Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma

Tang, Wilkin; Sun, Wei; Long, Guoxian

doi:10.1097/md.0000000000021785

Cited by 10 publications

(8 citation statements)

References 64 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding is supported by similar data [ 20 , 44 ], which confirmed that toxicity of platinum derivates and cetuximab is comparable. However, other authors have shown that BRT with cetuximab resulted in poorer overall survival, progression-free survival, locoregional control, and distant metastasis-free survival than cisplatin-based therapy [ 11 , 20 , 45 ]. Altogether, these results practically reduce the value of cetuximab in the treatment of advanced HNC, but cetuximab still remains a valuable option for patients with contraindications to platinum-based therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nutritional Care in Patients with Head and Neck Cancer during Chemoradiotherapy (CRT) and Bioradiotherapy (BRT) Provides Better Compliance with the Treatment Plan

Kapała

Surwiłło-Snarska

Jodkiewicz

et al. 2021

Cancers

View full text Add to dashboard Cite

The treatment of locally advanced head and neck cancer (HNC) is based on extensive resections followed by concurrent chemoradiotherapy (CRT) with platinum derivatives or concurrent radiotherapy with cetuximab (bioradiotherapy; BRT). Malnutrition, which occurs in up to 60% of patients before treatment commencement, severely increases the risk of CRT/BRT drug dose reductions and the incidence of treatment-related adverse events. A prospective observational study was performed regarding the influence of nutritional care on nutritional status, compliance with the treatment‘s planned regimen, and the incidence of treatment-related complications in patients with advanced HNC during CRT and BRT. The study population encompassed 153 patients compared with a retrospective control group of 72 patients treated before nutritional care was included in the standard of oncological care. Patients enrolled in the nutritional care programme received significantly higher doses of platinum derivatives or cetuximab than patients in the control group. A significant difference between the compared populations was observed in patients below 70 years of age (92.8% of the study population), after prior surgery, and with initial weight loss lower than 10%. Nutritional care reduced final weight loss and prevented a decline within the laboratory markers of nutritional status. Weight loss was comparable in both modes of treatment—CRT and BRT. The incidence of treatment-related complications was significantly higher in patients without nutritional support in the subgroups of patients under 70 years of age and after primary surgery. Nutritional care before and during CRT and BRT in patients with HNC is a determinant of therapeutic benefit, defined as preventing down-dosing, weight loss, and the incidence of complications. Platinum derivatives and cetuximab had comparable influence on weight loss.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Therefore, the treatment is based on extensive resections followed by concurrent chemoradiotherapy (CRT) with platinum derivatives or concurrent RTH with cetuximab (BRT) or on definitive concurrent chemoradiotherapy in inoperable cases [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Nutritional Care in Patients with Head and Neck Cancer during Chemoradiotherapy (CRT) and Bioradiotherapy (BRT) Provides Better Compliance with the Treatment Plan

Kapała

Surwiłło-Snarska

Jodkiewicz

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Currently, monoclonal antibodies such as cetuximab, that blocks EGFR activation, in combination with radiotherapy has been successfully used in the treatment of locoregionally advanced HNSCC, resulting in a better overall survival with low toxicity (Bonner et al, 2010). However, several clinical studies revealed that using cetuximab was detrimental in term of tumor control compared to other chemotherapeutic agents like cisplatin (Mehanna et al, 2019; Tang et al, 2020). It is evident from previous studies that activation of EGFR led to induction of EphB4, suggesting a functional interaction between these two cell membrane receptors (Masood et al, 2006; Park et al, 2015).…”

Section: Eph/ephrin Expression In Hnsccmentioning

confidence: 99%

A narrative review of the role of Eph receptors in head and neck squamous cell carcinoma

et al. 2023

View full text Add to dashboard Cite

Tyrosine kinase receptors (TKR) coordinate a variety of pathological processes in head and neck squamous cell carcinoma (HNSCC), and eventually play a role in patient outcomes. In this review, the role of Eph receptors in HNSCC progression and the possibility of targeting these receptors are illustrated. All relevant studies were identified through a comprehensive search of four electronic databases, including PubMed, Scopus, web of science, and Embase till August 2022. EphA2 and EphB4, along with ephrin‐B2, were the most extensively studied proteins in this family. However, overexpression of EphB4 and its ligand ephrin‐B2 were the only proteins that consistently showed association with a poor outcome, indicating that these proteins might serve as valuable prognostic markers in HNSCC. High expression of EphA3 and EphB4 was found to play a crucial role in radioresistance of HNSCC. EphB4 loss, in particular, was observed to induce an immunosuppression phenotypic HNSCC. Currently, ongoing clinical trials are investigating the benefits of EphB4‐ephrin‐B2 blockade in combination with standard of care treatment in HNSCC. Further efforts are needed to explore the biological role and behavioral complexity of this family of TKR in HNSCC with great attention to avoid heterogeneity of HNSCC subsites.

show abstract

“…Concurrent chemoradiotherapy is an established therapeutic option for advanced HNSCC [ 4 ]. In randomized trials, concurrent chemo- and radiotherapy improved survival rates [ 5 , 6 ]. These promising results suggest that this combination can enhance local and regional disease control in the head and neck, the most common region of relapse [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Serum Pro-Inflammatory Cytokines and Leptin as Potential Biomarkers for Treatment Response and Toxicity in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Alrehaili,

Gharib,

Bakhuraysah

et al. 2024

Diseases

View full text Add to dashboard Cite

Squamous cell carcinoma of the head and neck (HNSCC) is a globally prevalent form of cancer with significant morbidity and mortality rates. The present study examines the relationship of serum pro-inflammatory cytokines and leptin levels with the effectiveness of therapy in individuals with HNSCC and their potential role as biomarkers for treatment response and toxicity. Induction chemotherapy and concomitant chemoradiotherapy were evaluated for efficacy and safety in 52 individuals with HNSCC. Both response and toxicity were evaluated, and serum levels of pro-inflammatory cytokines Interlukin-1 beta (IL-1β), Interlukin-2 (IL-2), Interlukin-6 (IL-6), and Tumor Necrosis Factor-Alpha (TNF-α) and leptin were measured using enzyme-linked immunoassay before and after treatment. Before treatment, these measurements were made in comparison with a control group with 50 healthy people. The results showed that serum cytokines and leptin levels varied depending on the response to treatment, with patients who had a complete or partial response (PR) showing significant decreases in IL-1 β, IL-6, and TNF-α levels and significant increases in IL-2 and leptin levels after treatment, with an improvement in cachexia. These results imply that variations in serum pro-inflammatory cytokines and leptin levels are likely related to the therapeutic effectiveness in HNSCC and may act as biomarkers for treatment response.

show abstract

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma

Abstract: Supplemental Digital Content is available in the text

Cited by 10 publications

References 64 publications

Nutritional Care in Patients with Head and Neck Cancer during Chemoradiotherapy (CRT) and Bioradiotherapy (BRT) Provides Better Compliance with the Treatment Plan

Nutritional Care in Patients with Head and Neck Cancer during Chemoradiotherapy (CRT) and Bioradiotherapy (BRT) Provides Better Compliance with the Treatment Plan

A narrative review of the role of Eph receptors in head and neck squamous cell carcinoma

Serum Pro-Inflammatory Cytokines and Leptin as Potential Biomarkers for Treatment Response and Toxicity in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Contact Info

Product

Resources

About